Faiez ZANNAD - Paris, France
Faiez Zannad is Professor of Therapeutics at the University of Lorraine, Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux”, Nancy, France. He is a cardiologist and heart failure (HF) specialist with a PhD in clinical pharmacology (Oxford, UK).
Professor Zannad leads two EU FP7 granted programs: HOMAGE and FIBROTARGETS. As the primary investigator, or member, of oversight committees of major clinical trials, he pioneered and/or made significant contributions to evidence-based therapy for HF and beta-blockers as well as for major comorbid diseases in HF such as sleep disordered breathing, autonomic nervous dysfunction, diabetes, hyperkalemia, chronic kidney disease, and thrombosis.
He served as Chairman of the French Society of Hypertension, Chairman of the European Society of Cardiology (ESC) Working Group on pharmacology and drug therapy, and board member of the Heart Failure Association (HFA) of the ESC. He is the founder of, and is currently organizing, the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop; an annual international think tank gathering, dedicated to the science of clinical trials, with meetings in Paris and Washington DC, and in the Middle East and Asia. Professor Zannad has published more than 600 peer-reviewed papers, and several books and book chapters. He was awarded the 2014 European Society of Hypertension Paul Milliez Award and the 2017 Lifetime Achievement Award from the HFA of the ESC.